Rituximab for rheumatoid arthritis
28 results
1 - 28
Rituximab for rheumatoid arthritis 
Rituximab for rheumatoid arthritis: Cochrane systematic review- Rheumatoid arthritis
- Biologics for rheumatoid arthritis: an overview of Cochrane reviews
- Biologics for people with rheumatoid arthritis naive to methotrexate
- Biologic interventions for fatigue in rheumatoid arthritis
- Biologics for rheumatoid arthritis
- Infections in immunosuppressed and cancer patients
- Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease‐modifying anti‐rheumatic drugs: a systematic review and network meta‐analysis
- Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta‐analysis
- Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics
- Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti‐rheumatic drugs for rheumatoid arthritis: A network meta‐analysis
- Combination therapy in rheumatoid arthritis
- Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis
- Interventions for minimal change disease in adults with nephrotic syndrome
Biologicals improve outcomes in patients with RA- Chronic diseases and pregnancy
- Adverse effects of biologics: a network meta‐analysis and Cochrane overview
- Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease‐modifying anti‐rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta‐analysis (NMA)